What is the debt of Sartorius Stedim Biotech this year?
Sartorius Stedim Biotech has a debt level of 3,565.3 EUR this year.
In 2024, Sartorius Stedim Biotech's total debt was 3,565.3 EUR, a 246.62% change from the 1,028.6 EUR total debt recorded in the previous year.
Sartorius Stedim Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Analyzing Sartorius Stedim Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Investors pay close attention to Sartorius Stedim Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Shifts in Sartorius Stedim Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Sartorius Stedim Biotech has a debt level of 3,565.3 EUR this year.
The debt of Sartorius Stedim Biotech has increased by 246.62% compared to the previous year increased.
High debt can pose a risk for investors of Sartorius Stedim Biotech, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
Low debt means that Sartorius Stedim Biotech has a strong financial position and is able to fulfill its obligations without overburdening its finances.
An increase in debt of Sartorius Stedim Biotech can adversely affect the financial condition of the company and result in a higher burden on its finances.
A reduction in debt of Sartorius Stedim Biotech can strengthen the company's financial position and improve its ability to meet its financial obligations.
Some factors that can influence the debt of Sartorius Stedim Biotech include investments, acquisitions, operating costs, and revenue development.
The debts of Sartorius Stedim Biotech are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
To change the debt, Sartorius Stedim Biotech can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
Over the past 12 months, Sartorius Stedim Biotech paid a dividend of 2.88 EUR . This corresponds to a dividend yield of about 1.68 %. For the coming 12 months, Sartorius Stedim Biotech is expected to pay a dividend of 3.69 EUR.
The current dividend yield of Sartorius Stedim Biotech is 1.68 %.
Sartorius Stedim Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, May.
Sartorius Stedim Biotech paid dividends every year for the past 27 years.
For the upcoming 12 months, dividends amounting to 3.69 EUR are expected. This corresponds to a dividend yield of 2.15 %.
Sartorius Stedim Biotech is assigned to the 'Health' sector.
To receive the latest dividend of Sartorius Stedim Biotech from 4/4/2024 amounting to 0.69 EUR, you needed to have the stock in your portfolio before the ex-date on 4/2/2024.
The last dividend was paid out on 4/4/2024.
In the year 2023, Sartorius Stedim Biotech distributed 2.52 EUR as dividends.
The dividends of Sartorius Stedim Biotech are distributed in EUR.
The Sartorius Stedim Biotech stock can be added to a savings plan with the following providers: Trade Republic
Our stock analysis for Sartorius Stedim Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius Stedim Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.